Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial | JOURNAL OF CLINICAL ONCOLOGY |